Essais liés2clinical trials
VilleJerusalemlocalisation
PaysIsraellocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06392386

Ouvrir le site du centre

Essais cliniques associés

2
MoléculeIndication / populationPhaseNCTTitreStatut
Efgartigimod PH20 SC Myasthénie Phase 2/3 NCT06392386 ADAPT Jr SC — A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis RECRUITING
Efgartigimod IV or Efgartigimod PH20 SC Myasthénie Phase 2/3 NCT05374590 ADAPT Jr + — Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis ENROLLING_BY_INVITATION